Additional Transfer Sample Clauses

Additional Transfer. If any Purchased Patent is subject to a Disclaimer Issue after the Effective Date with respect to any other patent or patent application of Seller or its Affiliates, Seller shall transfer, and hereby does transfer, ownership of such patent or patent application to Purchaser without additional consideration and such patent or patent application shall be a Purchased Patent.
AutoNDA by SimpleDocs
Additional Transfer. Following the initial transfer described in Section 4.3.1, Company will provide updates to Vertex [***] per [***] regarding any newly acquired or generated Licensed Know-How, including information concerning any Products or Licensed Agents, and improved procedures for synthesis or manufacture of Licensed Agents or Product. As reasonably requested by Vertex, Company will promptly provide Vertex with any specific information included in the Licensed Technology that is necessary or useful for Vertex to Exploit the Licensed Compounds or Products. Company will provide such information to Vertex within [***] after Vertex’s request.
Additional Transfer. During the Term, in the event that Context reasonably believes additional BioAtla Know-How is necessary for the continued Exploitation of the Licensed Antibodies or Program Products, Context may reasonably request a copy of such additional BioAtla Know-How from BioAtla. BioAtla will transfer to Context a copy of such additional BioAtla Know-How, including any documentation (whether held in paper or electronic format) or similar removable media.
Additional Transfer. In addition to, and within sixty (60) days following, the transfer of assets from the Abbott ARP to the Hospira ARP described in Section 4.1(b) of this Agreement, Abbott shall pay Hospira an amount equal to that amount which, if contributed by Hospira to the Hospira ARP immediately following the transfer of assets required by Section 4.1(b) of this Agreement, would cause the ABO Funded Ratio of the Hospira ARP and the Abbott ARP to be equivalent as of the Distribution Date. With respect to a plan, the ABO Funded Ratio shall equal the fair market value of assets of that plan divided by the Accumulated Benefit Obligation of that plan, as determined under FAS 87. In calculating the ABO Funded Ratio, the assets for the Hospira ARP shall include the amount transferred directly from the Abbott ARP in accordance with Section 4.1(b) of this Agreement and the amount to be paid by Abbott in accordance with this Section 4.1(c). The pro-rata share of the 2003 plan year contributions assigned to the Abbott ARP in 4.1(b), that are contributed following the Distribution Date, shall be taken into account for purposes of calculating the ABO Funded Ratio of the Abbott ARP as of the Distribution Date as if those contributions had been part of the assets of the Abbott ARP on the Distribution Date. Similarly, the pro-rata share of the 2003 plan year contributions assigned to the Hospira ARP in Section 4.1(b) of this Agreement, that are contributed following the Distribution Date, shall be taken into account for purposes of calculating the ABO Funded Ratio of the Hospira ARP as of the Distribution Date as if those contributions had been part of the assets of the Hospira ARP on the Distribution Date. With the exception of the discount rate, the Accumulated Benefit Obligation shall be calculated using the assumptions and methodology used to calculate Xxxxxx'x December 31, 2003, FAS 87 disclosure information. The discount rate shall be determined as of the Distribution Date using Xxxxxx'x FAS 87 discount rate setting methodology consistent with Xxxxxx'x past practices. Hospira shall not be required to reimburse Abbott for any tax benefit received by Hospira with respect to any contribution to the Hospira ARP. 16 <Page> (d)
Additional Transfer. Notwithstanding any other provision of this Agreement, no Transfer of Subordinated Notes or of Warrants shall be effected unless any Transfer of Subordinated Notes is accompanied by a Transfer (to the same transferee) of Warrants having an aggregate Warrant Exercise Price (as defined in the Warrant Instrument) equal to the aggregate principal amount of the Subordinated Notes the subject of the Transfer, and vice versa.
Additional Transfer. The Seller agree transfer additional equity interest/ownership of Ticode to the Buyer as follows:

Related to Additional Transfer

  • Material Transfer In order to facilitate the Research Program and Joint Development Plans, either Party may provide to the other Party certain biological materials or chemical compounds including, but not limited to AVEO Molecules, receptors, assays, reagents and screens (collectively, “Materials”) owned by or licensed to the supplying Party (other than under this Agreement) for use by the other Party in furtherance of the Research Program and/or the Joint Development Plans. Except as otherwise provided under this Agreement, all such Materials delivered to the other Party shall, subject to the licenses granted the other Party pursuant to Article 6, remain the sole property of the supplying Party, shall be used only in furtherance of the Research Program and/or the Joint Development Plans, as applicable, and solely under the control of the other Party and/or its Affiliates, shall not be used or delivered to or for the benefit of any Third Party without the prior written consent of the supplying Party, and shall not (without the prior written consent of the supplying Party) be used in research or testing involving human subjects. The Materials supplied under this Section 10.6 must be used with prudence and appropriate caution in any experimental work, since not all of their characteristics may be known. Each Party represents and warrants to the other that it has the right to provide the Materials to the other Party for the uses contemplated herein. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE X, THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!